Nazione: Australia
Lingua: inglese
Fonte: Department of Health (Therapeutic Goods Administration)
Olanzapine benzoate
Synthon Au Pty Ltd
Medicine Registered
OLANZAPINE-SYNTHON CMI APRIL 2012 Page 1 of 8 OLANZAPINE-SYNTHON _Olanzapine benzoate _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet is designed to provide you with answers to some common questions about this medicine. It does not contain all the available information and does not take the place of talking with your doctor. All medicines have risks and benefits. Your doctor has more information about this medicine than is contained in this leaflet. Also, your doctor has had the benefit of taking a full and detailed history from you and is in the best position to make an expert judgement to meet your individual needs. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, TALK TO YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THIS MEDICINE. You may need to read it again. WHAT OLANZAPINE-SYNTHON IS USED FOR OLANZAPINE-SYNTHON is used to treat symptoms of schizophrenia and related psychoses. Olanzapine-Synthon alone, or in combination with lithium or valproate, is used for the short-term treatment of acute manic episodes associated with Bipolar I Disorder. OLANZAPINE-SYNTHON is also a mood stabiliser that prevents further occurrences of the disabling high and low (depres Leggi il documento completo
OLANZAPINE-SYNTHON- PRODUCT INFORMATION APRIL 2012 Page 1 of 19 OLANZAPINE-SYNTHON TABLETS _Olanzapine benzoate _ PRODUCT INFORMATION NAME OF THE MEDICINE OLANZAPINE-SYNTHON TABLETS (olanzapine benzoate) DESCRIPTION Chemical Name: 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno [2,3- b][1,5]benzodiazepine benzoate. Olanzapine is a yellow crystalline powder that is practically insoluble in water with a molecular weight of 312.44. Molecular Weight: 434.56 M olecular Formula: C 17 H 20 N 4 S.C 7 H 6 O 2 CAS number: 861452- 88-2 DESCRIPTION The active ingredient in Olanzapine-Synthon is olanzapine benzoate. Olanzapine- Synthon also contains the excipients: calcium hydrogen phosphate, cellulose- microcrystalline, sodium starch glycollate type A and magnesium stearate. PHARMACOLOGY PHARMACODYNAMICS Olanzapine is an atypical antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacological profile across a number of receptor systems. In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nmol) for serotonin 5HT 2A/2C , 5HT 3 , 5HT 6 ; dopamine D 1 , D 2 , D 3 , D 4 , D 5 ; cholinergic muscarinic receptors m 1 - m 5 ; alpha 1 adrenergic; and histamine H 1 receptors. Animal behavioural studies with olanzapine indicated 5HT, dopamine and cholinergic antagonism, consistent with the receptor binding profile. Olanzapine demonstrated a greater in-vitro affinity for serotonin 5HT 2 than dopamine D 2 receptors Leggi il documento completo